Gene Therapy for Leber Congenital Amaurosis
The National Eye Institute (NEI) seeks research co-development partners and/or licensees for the development of an AAV gene therapy for Leber Congenital Amaurosis caused by CEP290 mutations.
RS-1 Knockout Mouse Model for X-Linked Retinoschisis (XLRS) Research
The National Eye Institute (NEI) seeks research co-development partners and/or licensees for the development of a transgenic mouse model for X-linked retinoschisis (XLRS).
A Method to Remove Fluid-motion Related Artifacts in Magnetic Resonance Thermometry Images Using Magnetic Field Gradients
This technology includes the incorporation of a magnetic field gradient waveform (consisting of two or more pulses) between excitation and encoding to eliminate signal from moving fluid for imaging applications. Proton Resonance Frequency (PRF) thermometry is a widely used Magnetic Resonance Imaging (MRI) based technique to monitor changes in tissue temperature in response to thermal therapy. The use of PRF thermometry with thermal therapy procedures is indispensable to ensure delivery of desired thermal dose to the target tissue, and to minimize unintended damage to the normal tissue.
Advancements in Postexposure Prophylaxis: Evaluating High-Potency Rabies-Neutralizing Monoclonal Antibodies
This technology represents a significant advancement in the field of rabies prevention, focusing on the development of highly potent rabies-neutralizing monoclonal antibodies (mAbs) for use in postexposure prophylaxis (PEP). With two mAbs, F2 and G5a, displaying exceptional neutralizing titers of 1154 and 3462 International Units (IUs) per milligram, respectively, these antibodies have the potential to offer enhanced protection against rabies when administered alongside rabies vaccines.
Monoclonal Antibody (RO4) that Reacts with the Juxta-membrane Region of Mesothelin
Summary:
The National Cancer Institute (NCI) seeks research co-development partners and/or licensees for a novel monoclonal antibody (mAb), RO4, that can be used to treat mesothelin (MSLN) expressing cancers.
Fatty Acid Derivatives and Their Use for the Treatment and Prevention of Autoimmune, Inflammatory, and Pain Disorders
The discovery and selection of suitable compounds for the treatment and prevention of autoimmune, inflammatory, and pain disorders is a significant challenge. Researchers at National Institute of Aging (NIA) mitigated this issue. They discovered and synthesized numerous novel fatty acid derivatives (novel small molecules) that may ameliorate these conditions and provide treatment options for these disorders. In a relevant rat model, the fatty acid derivatives developed by NIA demonstrated: